Steroid injection after EBD for stricture of esophageal endoscopic therapy

Intralesional steroid injection after endoscopic balloon dilation for stricture after endoscopic therapy (EMR, ESD, PDT) for esophageal cancer: a randomized controlled study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180182

Enrollment

Registered

2019-03-26

Start date

2017-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer Esophageal cancer

Interventions

Randomization for Steroid injection group or non-injection group after endoscopic balloon dilation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Esophageal stricture after esophageal EMR, ESD, PDT. Patients have stricture symptom (Dysphagia score, more than 2) Pathological results are esophageal cancers. 3) Strictures are located in thoracic and abdominal esophagus. 4) No organ failure 5) More than 20 years old and less than 85 years old. 6) Written informed consent had been obtained

Exclusion criteria

Exclusion criteria: 1) Strictures are derived from esophageal cancer itself and Chemo-radiation therapy's scars. 2) Oral steroid intake. 3) Ulcers after endoscopic resection are remained. 4) Non-correctable coagulopathy, or undergoing anticoagulant therapy 5) Uncontrolled complication

Design outcomes

Primary

Measure	Time frame
Period between endoscopic balloon dilation and restenosis symptom	—

Secondary

Measure	Time frame
Improvement rate of dysphagia score, Safety of steroid injection to lacerations after endoscopic balloon dilation for esophageal endoscopic therapy scars, Adverse events	—

Contacts

Public ContactNoriko Matsuura

Osaka International Cancer Institute

matuura-no@mc.pref.osaka.jp+81-6-6945-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026